QPPV.COM KNOWLEDGE ASSESSMENT

Fidanacogene Elaparvovec: AAV Gene Therapy for Haemophilia B and Pharmacovigilance

Test your understanding of the concepts covered by Fidanacogene Elaparvovec: AAV Gene Therapy for Haemophilia B and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the main pharmacovigilance implication of using a high-activity factor IX variant?

Only very low factor IX activity needs to be monitored Higher expression is always beneficial and cannot create a safety concern Monitoring must consider both inadequate haemostasis and excessive activity associated with thrombosis Factor IX activity becomes irrelevant because the transgene is active permanently

Question 2 of 10 Which combination best captures the product's main pharmacovigilance dimensions?

Vector immunity, liver biology and haemostatic outcomes Renal clearance, gastrointestinal absorption and antibiotic resistance Infusion volume, tablet dissolution and renal replacement therapy Skin distribution, pulmonary deposition and antimicrobial activity

Question 3 of 10 How should the EU status described in the article be characterised?

The EU authorisation was withdrawn for a confirmed safety signal The EU authorisation was withdrawn at the marketing authorisation holder's request for commercial reasons, and the product had not been marketed in the EU The EU authorisation remained fully active after commercialisation was terminated The product was rejected in the EU before any authorisation was granted

Question 4 of 10 Which finding would most directly support concern about excessive haemostatic effect rather than inadequate factor IX expression?

A thrombotic event occurring with high factor IX activity A bleed after major trauma with very low factor IX activity A transient infusion reaction during administration A reduction in factor IX activity accompanied by increased factor use

Question 5 of 10 A patient develops aminotransferase elevations after treatment. Which additional information is most important for understanding the potential relationship between hepatic toxicity and efficacy?

The patient's blood group alone Contemporaneous factor IX activity and the timing of corticosteroid treatment The number of infusion bags used Whether the patient previously used oral analgesics, without any timing information

Question 6 of 10 How should a later decline in factor IX activity generally be interpreted?

It is automatically an adverse reaction caused by the vector It is automatically proof that the product lacks efficacy It may reflect reduced durability, immune-mediated loss, assay variability or another clinical change and requires contextual assessment It has no relevance unless a thrombotic event occurs

Question 7 of 10 Which governance arrangement is most appropriate for this type of gene therapy?

PV should work independently and avoid input from clinical, regulatory and product-quality functions Governance should define interfaces among PV, clinical teams, medical affairs, product quality, regulatory affairs and long-term follow-up Only the infusion team should review emerging durability and thrombosis data Regulatory status should be managed separately from all safety and follow-up systems

Question 8 of 10 Which data display would be most informative for aggregate review of this therapy?

A single total count of all adverse events Longitudinal factor IX, liver tests, bleed rates, rescue-factor use and corticosteroid exposure Only the number of patients infused on the first treatment day A list of infusion reactions without dates or outcomes

Question 9 of 10 Which statement best distinguishes acute infusion reactions from the principal long-term pharmacovigilance challenge?

Infusion reactions are irrelevant because the product is a gene therapy Infusion reactions require precise acute assessment, while long-term PV must also follow hepatic effects, expression and haemostatic outcomes Only delayed reactions should be recorded because acute events are expected Long-term monitoring is unnecessary once the infusion is tolerated

Question 10 of 10 Why is it useful to connect liver-test trajectories with factor IX trajectories in aggregate analysis?

Because every liver-test abnormality necessarily causes thrombosis Because hepatic immune injury may affect transduced hepatocytes and coincide with changes in factor IX expression Because liver tests directly measure vector antibody titres Because factor IX activity is determined exclusively by bilirubin concentration

Fidanacogene Elaparvovec: AAV Gene Therapy for Haemophilia B and Pharmacovigilance

Cookie Settings